Andrea Newkirk Analyst PerformanceAnalyst at The Goldman Sachs GroupAndrea Newkirk is a stock analyst at The Goldman Sachs Group in the healthcare sector, covering 16 publicly traded companies. Over the past year, Andrea Newkirk has issued 17 stock ratings, including buy, hold, and sell recommendations. While full access to Andrea Newkirk's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrea Newkirk's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings21 Last 1 YearsBuy Recommendations47.62% 10 Buy RatingsCompanies Covered16 Unique Companies Ratings Distribution21RatingsDistribution of strong buy, buy, hold, and sell ratings by Andrea Newkirk.RatingPercentageCount Strong Buy0.0%0 ratings Buy47.6%10 ratings Hold38.1%8 ratings Sell14.3%3 ratingsOut of 21 total stock ratings issued by Andrea Newkirk at The Goldman Sachs Group, the majority (47.6%) have been Buy recommendations, followed by 38.1% Hold and 14.3% Sell.Best & Worst CallsBest Call0000.0%RVMDJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ALKSJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ16 companiesAndrea Newkirk, an analyst at The Goldman Sachs Group, currently covers 16 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare16 companies100.0%Andrea Newkirk of The Goldman Sachs Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY13 companies81.3%PHARMACEUTICALS2 companies12.5%HEALTHCARE TECHNOLOGY1 company6.3% Andrea Newkirk's Ratings History at The Goldman Sachs Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsKODKodiak Sciences9/24/2026Initiated Coverage$31.52$36.00Neutral$0.0000.00% ROIALKSAlkermes9/24/2026Reiterated Rating$42.13$50.00Neutral$0.0000.00% ROITARSTarsus Pharmaceuticals9/24/2026Initiated Coverage$74.29$116.00Buy$0.0000.00% ROIRVMDRevolution Medicines9/24/2026Initiated Coverage$190.74$267.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals9/24/2026Initiated Coverage$513.02$704.00Buy$0.0000.00% ROIKRYSKrystal Biotech9/24/2026Initiated Coverage$341.75$441.00Buy$0.0000.00% ROIJAZZJazz Pharmaceuticals9/24/2026Initiated Coverage$234.88$337.00Buy$0.0000.00% ROIINSMInsmed9/24/2026Initiated Coverage$118.34$188.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics9/24/2026Initiated Coverage$10.19$15.00Buy$0.0000.00% ROISGMTSagimet Biosciences9/24/2026Initiated Coverage$10.42$7.00Sell$0.0000.00% ROIUTHRUnited Therapeutics9/24/2026Initiated Coverage$489.42$321.00Sell$0.0000.00% ROIMGTXMeiraGTx9/24/2026Initiated Coverage$11.75$16.00Neutral$0.0000.00% ROIABCLAbCellera Biologics9/24/2026Reiterated Rating$12.31$13.00Neutral$0.0000.00% ROIARWRArrowhead Pharmaceuticals9/24/2026Initiated Coverage$66.96$74.00Neutral$0.0000.00% ROIIOVAIovance Biotherapeutics2/5/2026Reiterated Rating$2.44$2.00Sell$0.0000.00% ROISDGRSchrodinger9/29/2025Initiated Coverage$20.04$19.00Neutral$0.0000.00% ROISDGRSchrodinger9/29/2025Upgrade$20.06Hold$0.0000.00% ROIRVMDRevolution Medicines9/12/2025Boost Price Target$46.25$73.00Buy$000.0000.00% ROIALKSAlkermes7/15/2025Initiated Coverage$29.69$43.00Buy$00.0000.00% ROIRVMDRevolution Medicines7/15/2025Initiated Coverage$38.37$65.00Buy$000.0000.00% ROIETNB89BIO3/14/2025Initiated Coverage$8.18$11.00Neutral$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageB. Riley FinancialUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
